Model & Strategy

The Problem
Each year, 10 million people die of cancer. Cancer patients urgently need more affordable and effective treatment options. Yet developing one new drug can take over a decade and $1B, and even then it may only extend survival by a few months and cost over $100,000 annually. Around 40% of cancer patients in the U.S. exhaust their life savings within two years of diagnosis. There is a major opportunity to reduce the time and cost of creating new cancer treatments — while also prioritizing globally accessible therapies — through the repurposing of FDA-approved generic drugs. However, a market failure stands in the way: repurposing generic drugs is not financially rewarding for pharmaceutical companies, and the government does not fund late-stage drug development, so potential treatments do not reach patients. Reboot Rx is dedicated to fixing this market failure, giving generic drugs a new life in oncology — and extending the lives of oncology patients with inexpensive treatments.

The Solution
Reboot Rx envisions a future where cancer patients worldwide have access to effective, low-cost treatment options that help them live longer and better lives. Using their AI technology powered by machine learning and natural language processing, Reboot Rx accelerates the drug development process, identifying high-potential drug candidates for repurposing in weeks instead of years. Using this innovative approach, Reboot Rx scientists identified promising generic drugs for prostate cancer, which have already been tested through Phase II clinical trials. They are now validating their findings with real-world evidence using electronic medical record data and results from larger clinical trials by partnering with healthcare systems like the VA. Reboot Rx will drive the adoption of generic drugs into the standard of care, increasing access for patients everywhere.

Over the next three years, Reboot Rx will identify the most promising generic drugs for multiple other cancer types and work to introduce these drugs into the standard of care for all patients. Scaling Reboot Rx’s approach for the 10 most common cancers could yield 30 additional promising generic drugs for repurposing, with the potential to quickly expand treatment options for 9 million patients each year, including the most vulnerable in the U.S. who often can’t afford the co-pays related to the cancer treatments prescribed and so forego care.

At a Glance
Founded: 2020
Founder & CEO: Laura Kleiman
Location of work: Domestic, Northeast, West Coast, Midwest, Southwest, Southeast, South Central
Reboot Rx
Boston, MA
Because the solution may already exist
Meet Laura Kleiman

Laura Kleiman, PhD, is the Founder and CEO of Reboot Rx. When her mother was diagnosed with cancer, Laura realized that a market failure is preventing effective and affordable treatments from rapidly reaching patients. She lost her mother and now passionately works to expand treatment options with repurposed generic drugs for future cancer patients.

Laura’s career is focused on building cross-sector collaborations to drive innovative and equitable development of new treatments for cancer patients. She holds a PhD in Computational and Systems Biology from MIT, was an American Cancer Society Postdoctoral Fellow at the Massachusetts General Hospital and Harvard Medical School, and served as Scientific Research Director in the Department of Data Sciences at the Dana-Farber Cancer Institute. Laura has been featured in Forbes, the Boston Business Journal, and Life Science Leader. She has been recognized with awards from The Commonwealth Institute’s Extraordinary Women Advancing Healthcare, 40 Under 40 in Cancer, the Massachusetts Life Sciences Center’s MassNextGen Initiative, and the Dana-Farber Cancer Institute. Laura is a Draper Richards Kaplan Foundation Entrepreneur and a Class of 2022 Henri Termeer Fellow, a prestigious appointment for emerging CEOs within the life science industry who show great promise for bringing life-saving treatments to patients.


In only 12 weeks, Reboot Rx deployed their AI technology to synthesize clinical data from 16,000 published studies and identified the top non-cancer generic drugs to repurpose for prostate cancer.

One of these drugs costs just $50 per year and could prevent or delay prostate cancer progression for 80,000 patients and save $4 billion in healthcare costs each year worldwide.

Scaling Reboot Rx’s approach for the 10 most common cancers could yield 30 additional promising generic drugs for repurposing, with the potential to quickly expand treatment options for 9 million cancer patients each year.